Estimation of potency of HERG channel blockers: impact of voltage protocol and temperature (Q40413448)

20 September 2017

title

Estimation of potency of HERG channel blockers: impact of voltage protocol and temperature (English)

1 reference

20 September 2017

Jian-An Yao

1

1 reference

20 September 2017

Xiaoyi Du

2

1 reference

20 September 2017

Daniel Lu

3

1 reference

20 September 2017

Robert L Baker

4

1 reference

20 September 2017

Eric Daharsh

5

1 reference

20 September 2017

Philip Atterson

6

1 reference

20 September 2017

language of work or name

1 reference

1 July 2005

1 reference

Journal of Pharmacological and Toxicological Methods

20 September 2017

published in

1 reference

20 September 2017

volume

52

1 reference

20 September 2017

issue

1

1 reference

20 September 2017

page(s)

146-153

1 reference

Modulation of human erg K+ channel gating by activation of a G protein-coupled receptor and protein kinase C.

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.04.008

QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.04.008

14-3-3 amplifies and prolongs adrenergic stimulation of HERG K+ channel activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.04.008

Regulation of the cardiac repolarizing HERG potassium channel by protein kinase A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.04.008

Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.04.008

A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.04.008

Preferential closed channel blockade of HERG potassium currents by chemically synthesised BeKm-1 scorpion toxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.04.008

Cardiotoxicity of new antihistamines and cisapride

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.04.008

A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.04.008

Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.04.008

Characterisation of recombinant HERG K+ channel blockade by the Class Ia antiarrhythmic drug procainamide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.04.008

HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.04.008

Class III antiarrhythmic drugs block HERG, a human cardiac delayed rectifier K+ channel. Open-channel block by methanesulfonanilides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.04.008

Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.04.008

Human ether-a-gogo related gene (HERG) K+ channels as pharmacological targets: present and future implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.04.008

Comparison of kinetic properties of quinidine and dofetilide block of HERG channels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.04.008

Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.04.008

Comparative effects of azimilide and ambasilide on the human ether-a-go-go-related gene (HERG) potassium channel.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.04.008

Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.04.008

Azimilide (NE-10064) can prolong or shorten the action potential duration in canine ventricular myocytes: dependence on blockade of K, Ca, and Na channels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.04.008

BeKm-1 Is a HERG-Specific Toxin that Shares the Structure with ChTx but the Mechanism of Action with ErgTx1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.04.008

Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.04.008

10.1016/J.VASCN.2005.04.008

7 January 2021

Identifiers

DOI

1 reference

20 September 2017

1 reference